368 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Coalition urges FTC block to ABBV-AGN deal https://seekingalpha.com/news/3499276-coalition-urges-ftc-block-abbv-agn-deal?source=feed_news_all Sep 13, 2019 - Consumer groups and unions want the FTC to block AbbVie's (ABBV +0.4%) $63B acquisition of Allergan (AGN), according to a STAT report.The coalition says the increasingly concentrated nature of the hea
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment http://www.zacks.com/stock/news/516990/ardelyx-gets-fda-approval-for-ibsrela-as-ibs-c-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-516990 Sep 13, 2019 - Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others http://www.zacks.com/stock/news/516828/pharma-stock-roundup-pipeline-regulatory-updates-from-gsk-pfe-others?cid=CS-ZC-FT-analyst_blog|stock_roundup-516828 Sep 13, 2019 - Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe http://www.zacks.com/stock/news/512573/allergans-filings-for-abicipar-pegol-accepted-in-us-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-512573 Sep 11, 2019 - The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
ETFs Poised to Benefit from Gene Editing Revolution http://www.zacks.com/stock/news/505549/etfs-poised-to-benefit-from-gene-editing-revolution?cid=CS-ZC-FT-etf_news_and_commentary-505549 Sep 06, 2019 - Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs http://www.zacks.com/stock/news/505264/pharma-stock-roundup-agns-opioid-settlement-line-extension-nod-in-eu-for-mrk-jnj-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-505264 Sep 06, 2019 - Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
How Will Johnson & Johnson's Opioid Case Ruling Impact Big Pharma Stocks? https://www.fool.com/investing/2019/09/05/how-will-johnson-johnsons-opioid-case-ruling-impac.aspx?source=iedfolrf0000001 Sep 05, 2019 - Investors need to be careful about which pharmaceutical stocks they own.
Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease http://www.zacks.com/stock/news/503280/endo-gains-fda-nod-for-orfadin-generic-to-treat-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-503280 Sep 05, 2019 - Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrum's Orfadin.
Company News For Jun 20, 2019 http://www.zacks.com/stock/news/432199/company-news-for-jun-20-2019?cid=CS-ZC--432199 Jun 20, 2019 - Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data http://www.zacks.com/stock/news/431676/biotech-stock-roundup-amgen-gets-fda-nod-for-kanjinti-regeneron-presents-data?cid=CS-ZC-FT-431676 Jun 19, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Pages: 12345678...37

<<<Page 3>